Fecal microbiota transplantation influences microbiota without connection to symptom relief in irritable bowel syndrome patients

Anna K. Hartikainen, Jonna Jalanka, Perttu Lahtinen, Alise J. Ponsero, Tuomas Mertsalmi, Laura Finnegan, Fiona Crispie, Paul D. Cotter, Perttu Arkkila, Reetta Satokari

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

Abstrakti

Imbalanced microbiota may contribute to the pathophysiology of irritable bowel syndrome (IBS), thus fecal microbiota transplantation (FMT) has been suggested as a potential treatment. Previous studies on the relationship between clinical improvement and microbiota after FMT have been inconclusive. In this study, we used 16S rRNA gene amplicon and shotgun metagenomics data from a randomized, placebo controlled FMT trial on 49 IBS patients to analyze changes after FMT in microbiota composition and its functional potential, and to identify connections between microbiota and patients’ clinical outcome. As a result, we found that the successful modulation of microbiota composition and functional profiles by FMT from a healthy donor was not associated with the resolution of symptoms in IBS patients. Notably, a donor derived strain of Prevotella copri dominated the microbiota in those patients in the FMT group who had a low relative abundance of P. copri pre-FMT. The results highlight the multifactorial nature of IBS and the role of recipient’s microbiota in the colonization of donor’s strains.

Alkuperäiskielienglanti
Artikkeli73
Lehtinpj Biofilms and Microbiomes
Vuosikerta10
Numero1
Sivumäärä10
ISSN2055-5008
DOI - pysyväislinkit
TilaJulkaistu - 2024
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Lisätietoja

Publisher Copyright:
© The Author(s) 2024.

Tieteenalat

  • 3111 Biolääketieteet
  • 3121 Yleislääketiede, sisätaudit ja muut kliiniset lääketieteet

Siteeraa tätä